In a 6-week double-blind trial in MDD, adding rosiglitazone 2 mg every 12 h to sertraline reduced HDRS scores more than placebo (week 6 Cohen's d 0.54). Response was 84.4% vs 51.5%; remission did not differ significantly (18.8% vs 9.1%). Side effects were comparable.
RCT
Shamabadi et al. Rosiglitazone Adjunct to Sertraline for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial